RT Journal Article SR Electronic T1 Back-to-Africa introductions of Mycobacterium tuberculosis as the main cause of tuberculosis in Dar es Salaam, Tanzania JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.09.29.22280296 DO 10.1101/2022.09.29.22280296 A1 Zwyer, Michaela A1 Rutaihwa, Liliana K. A1 Windels, Etthel A1 Hella, Jerry A1 Menardo, Fabrizio A1 Sasamalo, Mohamed A1 Borrell, Sonia A1 Reinhard, Miriam A1 Dötsch, Anna A1 Hiza, Hellen A1 Stritt, Christoph A1 Sikalengo, George A1 Fenner, Lukas A1 De Jong, Bouke C. A1 Kato-Maeda, Midori A1 Jugheli, Levan A1 Ernst, Joel D. A1 Niemann, Stefan A1 Jeljeli, Leila A1 Ballif, Marie A1 Egger, Matthias A1 Rakotosamimanana, Niaina A1 Yeboah-Manu, Dorothy A1 Asare, Prince A1 Malla, Bijaya A1 Dou, Horng Yunn A1 Zetola, Nicolas A1 Wilkinson, Robert J. A1 Cox, Helen A1 Carter, E Jane A1 Gnokoro, Joachim A1 Yotebieng, Marcel A1 Gotuzzo, Eduardo A1 Abimiku, Alash’le A1 Anchalee, Avihingsanon A1 Xu, Zhi Ming A1 Fellay, Jacques A1 Portevin, Damien A1 Reither, Klaus A1 Stadler, Tanja A1 Gagneux, Sebastien A1 Brites, Daniela YR 2022 UL http://medrxiv.org/content/early/2022/09/30/2022.09.29.22280296.abstract AB In settings with high tuberculosis (TB) endemicity, various genotypes of the Mycobacterium tuberculosis complex (MTBC) often differ in prevalence. However, the factors leading to these differences remain poorly understood. Here we studied the MTBC population in Dar es Salaam, Tanzania over a six-year period, using 1,082 unique patient-derived MTBC whole-genome sequences (WGS) and associated clinical data. We show that the TB epidemic in Dar es Salaam is dominated by multiple genotypes introduced to Tanzania from different parts of the world during the last 300 years. The most common MTBC genotypes deriving from these introductions exhibited differences in transmission rates and in the duration of the infectious period, but little differences in overall fitness, as measured by the effective reproductive number. Moreover, measures of disease severity and bacterial load indicated no differences in virulence between these genotypes during active TB. Instead, the combination of an early introduction and a high transmission rate accounted for the high prevalence of L3.1.1, the most dominant MTBC genotype in our setting. Yet, a longer co-existence with the host population did not always result in a higher transmission rate, suggesting that distinct life-history traits have evolved in the different MTBC genotypes. Taken together, our results point to bacterial factors as important determinants of the TB epidemic in Dar es Salaam.Author summary Tuberculosis (TB) is the deadliest human infectious disease caused by one single agent, Mycobacterium tuberculosis (Mtb). The origins of Mtb have been traced to East Africa millennia ago, where it likely became adapted to infect and transmit in humans. Here we show that in Dar es Salaam, Tanzania, an East African setting with a very high burden of TB, infections are caused by distinct Mtb genotypes introduced in recent evolutionary times from different parts of the world. These genotypes differed in traits important to Mtb transmission in the Dar es Salaam host population; while some Mtb genotypes transmitted more efficiently during a certain period of time, others elicited that patients would be infectious for longer periods. These traits evolved independently in the different Mtb genotypes and could not be explained by the time of co-existence between the host population and the pathogen. This suggests that bacterial factors are important determinants of the TB epidemic. More generally, we demonstrate that distinct pathogenic life history characteristics can co-exist in one host population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Swiss National Science Foundation (https://www.snf.ch; Grant No: CRSII5_177163, 310030_188888) and the European Research Council (https://erc.europa.eu/; Grant No: 883582). RJW is supported by the Francis Crick Institute which receives funding from Wellcome (FC0010218), Cancer Research UK (FC0010218), and the Medical Research Council (FC0010218). He also receives support from Welcome (203135).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Nordwest und Zentralschweiz gave ethical approval for this work Ethics committee of Ifakara Health Institute Institutional Review Board board gave ethical approval for this work. Ethics committee of the National Institute for Medical Research in Tanzania Medical Research Coordinating Committee gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors